Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

The LMP1 promoter can be transactivated directly by NF-kappaB


Demetriades,  C.
Demetriades – Cell Growth Control in Health and Age-related Disease, Max Planck Research Groups, Max Planck Institute for Biology of Ageing, Max Planck Society;

External Resource
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Demetriades, C., & Mosialos, G. (2009). The LMP1 promoter can be transactivated directly by NF-kappaB. J Virol, 83(10), 5269-77. doi:10.1128/JVI.00097-09.

Cite as: https://hdl.handle.net/21.11116/0000-000B-A356-C
A bioinformatic analysis identified two putative NF-kappaB binding sites in the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) promoter. The ability of p65RelA to interact with the LMP1 promoter was shown by in vitro and in vivo assays. Using an EBV-transformed lymphoblastoid cell line as a reporter system for the activity of the +40/-328 LMP1 promoter region, the functional importance of NF-kappaB and other transcription factor binding sites was demonstrated. p65RelA could also induce LMP1 expression from the EBV genome in Daudi and P3HR1 Burkitt's lymphoma cell lines. Finally, it was shown that p65RelA could cooperate with EBNA2 or the aryl hydrocarbon receptor in the transactivation of the LMP1 promoter. Our study established the importance of NF-kappaB and several cis-acting elements in the regulation of the LMP1 promoter in a latency III environment and highlighted a complex interplay between NF-kappaB and other transcription factors in this process.